Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

The potential of using Verteporfin to prevent hair loss scars and possible regrowth, with two doctors currently testing it, although the price of a 15mg bottle is expensive.

User shares 6.5 months of progress using topical finasteride 0.1% and minoxidil 10%, along with lasercomb, dermaroller, Nizoral, scalp massager, and biotin. They seek feedback on their results.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Hair loss discussion includes microneedling and optimal needle lengths. Users suggest doing treatments at night for better healing.

A user wants to try melatonin for hair loss by mixing melatonin powder with a topical oil serum. They are asking if this mixture is possible and effective.

PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

User "missbloombastic" has been experiencing hair loss since 2016 and tried min, fin, multivitamins, and spiro with mixed results. Another user shares their struggle with hair loss and its impact on self-esteem, while a third user suggests checking blood tests and confirming the cause of hair loss.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

The conversation discusses hair thinning potentially linked to gut health issues and suggests biotin as a possible treatment. It also mentions that hair thinning could be due to male pattern baldness (MPB).

User considers adding Alfatradiol to their topical finasteride treatment for hair loss. Others discuss Alfatradiol as a weak estrogen and 5α-reductase inhibitor used for pattern hair loss in men and women.

The conversation discusses the use of Verteporfin in treating hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user experienced good hair regrowth over three months using a daily topical spray of 0.3% finasteride and 6% minoxidil on the hairline, with no significant side effects. The brand used was Hims.

Bimatoprost was discussed for hair loss, with concerns about long-term scalp effects. A user reported no substantial effect after 6 months of use.

Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.

The conversation discusses treating male pattern baldness with topical products containing Saw Palmetto extract. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

Minoxidil and spironolactone are used for hair regrowth, with visible progress noted. Spironolactone is discussed as a treatment option, particularly in the context of transitioning, with concerns about its effects on men.